DGAP-Adhoc

4SC Signs Licensing and Development Agreement with Menarini for Resminostat in Asia-Pacific Excluding Japan

4SC AG / Key word(s): Agreement/Alliance

14.04.2015 14:24

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

4SC Signs Licensing and Development Agreement with Menarini for Resminostat
in Asia-Pacific Excluding Japan

Planegg-Martinsried, Germany and Singapore, 14 April 2015 - 4SC AG
(Frankfurt, Prime Standard: VSC), a discovery and development company of
targeted small molecule drugs for cancer and autoimmune diseases, and
Singapore based Menarini Asia-Pacific Holdings Pte. Ltd. ("Menarini AP")
announced today that they have entered into a licensing and development
partnership for 4SC's cancer compound resminostat for the Asia-Pacific
region excluding Japan ("APAC").

Menarini AP, a member of the world's largest Italian biopharmaceutical
group, the Menarini Group, will receive the exclusive licensing rights for
the development and marketing of resminostat in all APAC countries,
including among others China, South Korea, Australia, Thailand,
Philippines, Indonesia, and Vietnam. Menarini AP will be responsible for
the clinical development, regulatory approval and commercialization of
resminostat in China, and other territories included in the agreement, in
all oncological indications, and in particular liver cancer (HCC).

4SC will receive upfront and milestone payments totaling approximately up
to EURO 95 million from Menarini payable upon achieving specified
development, regulatory and commercialization milestones. In addition, 4SC
will be eligible to double-digit royalties linked to product sales of
resminostat.


---------------------------------------------------------------------------

Information and Explaination of the Issuer to this News:

The development of resminostat in APAC, and China in particular, is of key
strategic importance to 4SC. Liver cancer (hepatocellular carcinoma, HCC),
a large cancer indication with limited therapeutic options and one of the
lead indications of resminostat's clinical development programme, has an
extremely high incidence in this region. More than 75% of all HCC cases
occur in the APAC region, largely in association with chronic hepatitis B
virus (HBV) infection. Approximately 50% of HCC cases globally occur in